chronic kidney disease

News

Bayer's Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.

News

Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying therapy for Alport syndrome.

Patients

A look at the benefits of genetic testing in diagnosis of rare kidney diseases, from HealthLumen.

News

An NHS trust in England is starting a pilot study of a digital health platform that promises to improve the care of people with kidney disease.

News

Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.

News

AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD).